Definium Therapeutics, Inc. (DFTX)
| Market Cap | 2.34B +391.0% |
| Revenue (ttm) | n/a |
| Net Income | -237.54M |
| EPS | -2.49 |
| Shares Out | 109.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,988 |
| Open | 20.80 |
| Previous Close | 20.87 |
| Day's Range | 20.70 - 21.13 |
| 52-Week Range | 6.35 - 26.25 |
| Beta | 2.38 |
| Analysts | Strong Buy |
| Price Target | 39.47 (+83.92%) |
| Earnings Date | May 7, 2026 |
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for DFTX stock is "Strong Buy." The 12-month stock price target is $39.47, which is an increase of 83.92% from the latest price.
News
Definium Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Phase III data for MDD are expected soon, with strong confidence in translatability from GAD and improved dropout rates. Regulatory preparations are advanced, aiming for rapid scheduling and market access. Commercial strategy leverages SPRAVATO’s model, emphasizing durability, payer value, and robust IP protection.
Definium Therapeutics says first patient dosed in Ascend study
Definium Therapeutics (DFTX) announced that the first patient has been dosed in Ascend, its second Phase 3 study evaluating DT120 ODT for the treatment of major depressive disorder. The Ascend…
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler
Piper Sandler analyst David Amsellem lowered the firm’s price target on Definium Therapeutics (DFTX) to $48 from $49 and keeps an Overweight rating on the shares following quarterly results. Taking…
Definium Therapeutics reports Q1 EPS (71c), consensus (49c)
As of March 31, 2026, Definium Therapeutics (DFTX) had cash, cash equivalents and investments of $373.4 million compared to $411.6 million as of December 31, 2025. Based on the Company’s…
Definium Therapeutics Earnings Call Transcript: Q1 2026
Late-stage clinical programs for DT120 ODT in MDD and GAD are progressing, with three pivotal phase III readouts expected in 2026. Q1 2026 saw increased R&D and G&A expenses, a net loss of $77.1 million, and a strong cash position of $373.4 million, supporting operations into 2028.
Definium Therapeutics Earnings release: Q1 2026
Definium Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Definium Therapeutics Quarterly report: Q1 2026
Definium Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics Slides: Corporate presentation
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
These 3 Psychedelic Stocks Activated After Trump's Executive Order
The Trump administration's April 2026 executive order in support of psychedelic drugs may have flown under the radar for many investors in the midst of the Iran war and numerous other high-profile dom...
Definium Therapeutics Proxy statement: Proxy filing
Definium Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Definium Therapeutics Proxy statement: Proxy filing
Definium Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Psychedelic: Exclusive talk with biopharma company Definium
In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Rob Barrow, Chief Executive Officer, and Daniel Karlin, Chief Medical Officer, at Definium Therapeutics (DFTX), a late-s...
Definium Therapeutics price target raised to $40 from $25 at Oppenheimer
Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $40 from $25 and keeps an Outperform rating on the shares. The firm attended Definium’s Investor and Analyst Day,…
Definium Therapeutics highlights advancement of DT120 ODT
Definium Therapeutics (DFTX) “highlighted the advancement of its DT120 ODT (lysergide tartrate) clinical program and commercial strategy in major depressive disorder and generalized anxiety disorder, ...
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics Transcript: Investor Day 2026
DT120 is advancing through multiple phase III trials for GAD, MDD, and PTSD, with three pivotal data readouts expected in 2024. The commercial strategy targets high-need patients and leverages robust IP, payer support, and operational learnings from esketamine. Strong clinical results and broad stakeholder engagement position DT120 for significant market impact.
Definium Therapeutics Slides: FY 2026
Definium Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 22, 2026.
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has b...
Psychedelic stocks rally with Trump's support
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.